What question did this study set out to answer?

To assess the 2-year efficacy, safety, and symptom response of ruxolitinib combined with low-dose pegylated interferon-α2 in patients with polycythemia vera or myelofibrosis.

December 26, 2019HaematologicaOpen Access

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

View Full Paper

Ask AI

Bookmark

Authors

ASAnders Lindholm Sørensen SMStine Ulrik Mikkelsen TKTrine Alma Knudsen

Discussion

Member takes

Overview

Randomized trial demonstrates remissions and reduced symptom burden in polycythemia vera and myelofibrosis, suggesting viable combination therapy.

Key Points

To assess the 2-year efficacy, safety, and symptom response of ruxolitinib combined with low-dose pegylated interferon-α2 in patients with polycythemia vera or myelofibrosis.
Conducted a 2-year phase II trial (EudraCT2013-003295-12) evaluating combination ruxolitinib and low-dose pegylated interferon-α2.
Enrolled 50 participants, comprising N=32 with polycythemia vera and N=18 with primary or secondary myelofibrosis, of whom 46 were previously intolerant of or refractory to pegylated interferon-α2.
Remission occurred in 31% (10/32) of patients with polycythemia vera (complete remission in 9% [3/32]) and in 44% (8/18) of patients with myelofibrosis (complete remission in 28% [5/18]).
Total symptom scores decreased from 22 (95% CI: 16–29) at baseline to 15 (95% CI: 10–22) after 2 years.
Median JAK2 V617F allele burden declined from 47% (95% CI: 33–61%) to 12% (95% CI: 6–22%), with 41% of participants reaching a molecular response.

Cite This Study

Sørensen et al. (2019) studied this question.

synapsesocial.com/papers/6a104ed0e1a472cb5efcaa24 https://doi.org/10.3324/haematol.2019.235648

View Full Paper

Ask AI

Bookmark

December 26, 2019HaematologicaOpen Access

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

View Full Paper

Ask AI

Bookmark

Authors

ASAnders Lindholm Sørensen SMStine Ulrik Mikkelsen TKTrine Alma Knudsen

Discussion

Member takes

Overview

Randomized trial demonstrates remissions and reduced symptom burden in polycythemia vera and myelofibrosis, suggesting viable combination therapy.

Key Points

To assess the 2-year efficacy, safety, and symptom response of ruxolitinib combined with low-dose pegylated interferon-α2 in patients with polycythemia vera or myelofibrosis.
Conducted a 2-year phase II trial (EudraCT2013-003295-12) evaluating combination ruxolitinib and low-dose pegylated interferon-α2.
Enrolled 50 participants, comprising N=32 with polycythemia vera and N=18 with primary or secondary myelofibrosis, of whom 46 were previously intolerant of or refractory to pegylated interferon-α2.
Remission occurred in 31% (10/32) of patients with polycythemia vera (complete remission in 9% [3/32]) and in 44% (8/18) of patients with myelofibrosis (complete remission in 28% [5/18]).
Total symptom scores decreased from 22 (95% CI: 16–29) at baseline to 15 (95% CI: 10–22) after 2 years.
Median JAK2 V617F allele burden declined from 47% (95% CI: 33–61%) to 12% (95% CI: 6–22%), with 41% of participants reaching a molecular response.

Cite This Study

Sørensen et al. (2019) studied this question.

synapsesocial.com/papers/6a104ed0e1a472cb5efcaa24 https://doi.org/10.3324/haematol.2019.235648

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark